



## Tango Therapeutics Named a “Fierce 15” Company by FierceBiotech

September 26, 2017

CAMBRIDGE, Mass.--([BUSINESS WIRE](#))--Tango Therapeutics, a biotechnology company creating novel, context-dependent medicines for cancer, today announced that it has been named by *FierceBiotech* as one of its Fierce 15 companies for 2017.

“We are thrilled to be named among the industry’s leading early innovators for our work in pioneering the discovery and development of new therapies based on the genetic concept of synthetic lethality, an untapped approach to treating cancer”

Fierce 15 showcases leading privately-held companies developing “products, services, or platforms that can advance the biotech industry and transform patient treatment.” According to *Fierce*, companies are selected based on “the strength of their technology, partnerships, venture backers and a competitive market position.”

“We are thrilled to be named among the industry’s leading early innovators for our work in pioneering the discovery and development of new therapies based on the genetic concept of synthetic lethality, an untapped approach to treating cancer,” said Barbara Weber, M.D., chief executive officer of Tango Therapeutics. “The talented and growing Tango team is making rapid strides in uncovering new drug targets in cancers that are created by tumor suppressor gene loss, and using these discoveries to develop new medicines with the potential for deeper and more durable responses for patients.”

### About Tango Therapeutics

Tango Therapeutics is a biotechnology company developing novel medicines for patients by discovering and drugging context-dependent vulnerabilities in cancers. Tango Therapeutics was launched in March 2017 with a \$55 million Series A investment from Third Rock Ventures and is headquartered in Cambridge, Mass. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that will provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango’s programs are focused on the area of synthetic lethality, the interaction between two genes that causes cell death when both are inactivated. For more information, please visit [www.tangotx.com](http://www.tangotx.com).

### About Third Rock Ventures

Third Rock Ventures is a leading healthcare venture firm focused on disruptive areas of science and medicine to discover, launch and build companies that make a dramatic difference in people’s lives. By combining our team’s scientific vision, strategic leadership, operational expertise and innovative deal-making capabilities, we nurture bold ideas that translate into successful business enterprises. Recognizing that the best way to create value for our investors is to create value for patients, our companies are built on a solid foundation of science, medicine, people and business strategy. For more information, please visit [www.thirdrockventures.com](http://www.thirdrockventures.com).

### About *FierceBiotech*

An internationally recognized daily report reaching a network of more than 275,000 biotech and pharma industry professionals, *FierceBiotech* provides subscribers with an authoritative analysis of the day’s top stories. Every business day, *FierceBiotech* and its family of publications covers the waterfront in drug development, from pre-clinical science to seed funding and venture capital, through IPOs and licensing, clinical testing, regulatory changes, M&A and beyond.

FierceBiotech is a publication of Questex LLC. Signup is free on this [registration page](#).

### Contacts

Ten Bridge Communications  
Dan Quinn, 781-475-7974  
[dan@tenbridgecommunications.com](mailto:dan@tenbridgecommunications.com)